Latest stories on IOVA
Best Momentum Stocks to Buy for October 27th
Yahoo Finance63 · neutralanalyst
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
Business Insider50 · neutralgeneral
Iovance’s lifileucel shows 50% response rate in soft tissue sarcomas
The Fly74 · bullishproduct/pr
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
Business Insider74 · bullishproduct/pr
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
GlobeNewswire74 · bullishproduct/pr
Iovance sees long-term response for Amtagvi in first-line melanoma
Seeking Alpha74 · bullishproduct/pr
Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End
Stocktwits News64 · neutralproduct/pr
Iovance’s Amtagvi shows durability in 1L melanoma, says Jefferies
The Fly64 · neutralanalyst
Iovance drops 3% to $13.67 after new melanoma data
The Fly42 · neutralgeneral
Iovance says one-time lifileucel showed 29.2% complete response rate
The Fly64 · neutralproduct/pr
Iovance brings lifileucel into new tumor types with first ESMO 2026 sarcoma oral data and frontline melanoma results
MarketChameleon64 · neutralproduct/pr
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
GlobeNewswire63 · neutralproduct/pr
Undercovered Dozen: Hess Midstream, Iovance Biotherapeutics, Netlist, And More
Seeking Alpha57 · neutralanalyst
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Iovance Biotherapeutics price target raised to $18 from $15 at Barclays
The Fly64 · neutralanalyst
Iovance Biotherapeutics price target raised to $11 from $6 at Baird
The Fly64 · neutralanalyst
Iovance Showcases Amtagvi Momentum and Growing TIL Leadership
TipRanks63 · neutralproduct/pr
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) files 8-K
SEC 8-K50 · neutralgeneral
Iovance: Buy Now Before Many Growth Catalysts Kick In
Seeking Alpha67 · bullishanalyst
Iovance Biotherapeutics appoints Berkowitz as CMO
The Fly56 · neutralgeneral